Peter DiLaura
Chief Executive Officer at Initial Therapeutics Inc
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mohamad Tabrizi | M | - |
ShangPharma Innovation, Inc.
 ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 7 years |
| Cheng Zhang | M | - |
Character Biosciences, Inc.
 Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | - |
| Robert A. Drakas | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 8 years |
| NIck Johnson | M | - |
Character Biosciences, Inc.
Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | - |
| Sander Duncan | M | - |
Lifeforce Capital Management, LLC
 Lifeforce Capital Management, LLC Investment ManagersFinance Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland. | 9 years |
| Rishi Sikka | M | - |
The Wharton School of the University of Pennsylvania
Lifeforce Capital Management, LLC
Lifeforce Capital Management, LLC Investment ManagersFinance Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland. | 7 years |
| Ya Jun Xu | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| John Noonan | M | - |
Lifeforce Capital Management, LLC
Lifeforce Capital Management, LLC Investment ManagersFinance Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland. | 10 years |
| Marcel van der Brug | M | - |
Character Biosciences, Inc.
Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | - |
| Juan-Carlos Lopez | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Grant Green | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 6 years |
| Jean Bidegainberry | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Sarah Lively | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Eric Parker | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| David Sahner | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| James H. Doudna Cate | M | - |
Initial Therapeutics Inc
 Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Rajesh Chopra | M | - |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Charles Yang | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Michael Ehlers | M | - |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Spiros Liras | M | - |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Rebecca Canter | F | - |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | 6 years |
| Nathan Bays | M | - |
Lifeforce Capital Management, LLC
Lifeforce Capital Management, LLC Investment ManagersFinance Lifeforce Capital Management, LLC (Lifeforce Capital) is a venture capital firm founded in 2015 by John Noonan. The firm is headquartered in Chevy Chase, Maryland. | - |
| Ruth McKernan | M | 66 |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | 6 years |
| Seth Harrison | M | 63 |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Stephen Munk | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Carole Nüchterlein | F | 62 |
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | 8 years |
| Vivek Garipalli | M | 45 |
Character Biosciences, Inc.
Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | - |
| Kevin Pojasek | M | - |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | 6 years |
| Olivia Mitchell | F | 71 |
The Wharton School of the University of Pennsylvania
| 31 years |
| Krishna Kodukula | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| David Spellmeyer | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 7 years |
| Xin Hui | M | 53 |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Joel Dudley | M | - |
Character Biosciences, Inc.
Character Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services The American company was founded by Nick Johnson, Cheng Zhang, and Marcel van der Brug, with Cheng Zhang serving as the CEO since incorporation. Character Biosciences is focused on developing therapies for ophthalmic and other progressive polygenic diseases. The company has developed a platform that integrates genomics with longitudinal clinical data to select drug targets and match therapies to the right patients. Currently, Character Biosciences is advancing two lead drug discovery programs through preclinical development for dry age-related macular degeneration. | 2 years |
| Dirk Brockstedt | M | 55 |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
| Michael Ehlers | M | - |
Initial Therapeutics Inc
Initial Therapeutics Inc BiotechnologyHealth Technology Opal Biosciences, Inc. operates as a biotechnology company. The company is headquartered in New York, NY. | - |
| Christian Billy Jung | M | 42 |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | 5 years |
| Ravi Kiron | M | 64 |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 7 years |
| Giles Platford | M | - | 7 years | |
| Robert Wild | M | 53 |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | 7 years |
| Robert Lutz | M | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Karim Dabbagh | M | - |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | 9 years |
| Yasuchika Hasegawa | M | 78 | 47 years | |
| David Perry | M | 56 |
Ventro Corp.
 Ventro Corp. Information Technology ServicesTechnology Services Ventro Corp. provides e-commerce solutions. | 4 years |
| Shinji Honda | M | 66 | 36 years | |
| Fumio Sudo | M | 83 | 6 years | |
| Bryce Markus | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Donna M. Walsh | F | - |
The Wharton School of the University of Pennsylvania
| 14 years |
| Adam Blackman | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Phil Bronner | M | 53 |
The Wharton School of the University of Pennsylvania
| 3 years |
| Andrew Pearson | M | 52 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Lawrence Berger | M | 52 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Justin Warren Slatky | M | - |
The Wharton School of the University of Pennsylvania
| 5 years |
| Maja M. Gross | F | - |
The Wharton School of the University of Pennsylvania
| 6 years |
| Matthew Young | M | 54 |
The Wharton School of the University of Pennsylvania
| 5 years |
| Rolando Gutíerrez-Esteinou | M | 63 | 1 years | |
| Bruce C. Miller | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Daniel Leonard Spears | M | 51 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Sapna Shah | F | - |
The Wharton School of the University of Pennsylvania
| 3 years |
| Richard Thompson | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Evan Eneman | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Richard Stevenson | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| William Shraga | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Lee B. Stephens | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| John C. Chan | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Jenny Lefcourt | F | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Clinton Andrew Hess | M | 53 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Shao Shan Wu | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Chi Yan Szeto | M | 49 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Robert W. Culver | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Chou Wang | M | 54 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Winston Chow | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Raj Gollamudi | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Jonathan Kelly | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| David P. Homer | M | 62 |
The Wharton School of the University of Pennsylvania
| 2 years |
| David Anthony Durkin | M | 55 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Gary Phillips | M | 58 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Michelle Peluso | F | 52 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Mitchell Krebs | M | 52 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Rocco Tarasi | M | 52 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Rob T. Coneybeer | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Neil I. Vogel | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Josh Kopelman | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Bruce L. Glazer | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Heather Carrillo | F | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Sean Traynor | M | 55 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Steven Collins | M | 55 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Julia Ossipov-Grodsky | F | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Rodd Macklin | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Stephen Kim | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Suresh Shanmugham | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Eric S. Weinstein | M | 53 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Chris Pucillo | M | 56 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Brian W. Sullivan | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Rahul Aggarwal | M | 49 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Weijian Shan | M | 70 |
The Wharton School of the University of Pennsylvania
| 6 years |
| Jalak Jobanputra | F | - |
The Wharton School of the University of Pennsylvania
| - |
| Roy Sehgal | M | - |
The Wharton School of the University of Pennsylvania
| 4 years |
| Steven Jones | M | 59 |
The Wharton School of the University of Pennsylvania
| 2 years |
| Brian S. Dunn | M | 52 |
The Wharton School of the University of Pennsylvania
| 4 years |
| Leigh Wasson | F | - |
The Wharton School of the University of Pennsylvania
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 95 | 95.00% |
| Japan | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter DiLaura
- Personal Network
